Global Peptide and Anticoagulant Drugs Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Global Peptide and Anticoagulant Drugs Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

  • Pharmaceutical
  • Upcoming Report
  • Jan 2025
  • Global
  • 350 Pages
  • Количество таблиц: 220
  • Количество рисунков: 60

Global Peptide And Anticoagulant Drugs Market

Размер рынка в млрд долларов США

CAGR :  % Diagram

Chart Image USD 1.83 Billion USD 2.93 Billion 2024 2032
Diagram Прогнозируемый период
2025 –2032
Diagram Размер рынка (базовый год)
USD 1.83 Billion
Diagram Размер рынка (прогнозируемый год)
USD 2.93 Billion
Diagram CAGR
%
Diagram Основные игроки рынка
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Global Peptide and Anticoagulant Drugs Market Segmentation, By Low Molecular Weight Heparin Type (Heparin Sodium, Enoxaparin Sodium, Dalteparin Sodium, and Fondaparinux), Type (Hormonal, Antibiotic, ACE Inhibitor, Antifungal, Others), Indication (Diabetes, Infectious Diseases, Cancer, Osteoporosis, Cardiology, Gynecology, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032

Peptide and Anticoagulant Drugs Market

Peptide and Anticoagulant Drugs Market Analysis    

Coronary heart disease and myocardial infarction (MI) are regarded a major public health concern around the world. In the United States, the number of patients who have coronary artery disease has increased noticeably. According to the American Heart Association (AHA), roughly one in every seven deaths in the United States occurred in 2018. According to the survey, adults with cardiac infection account for almost 7.9 million (3 percent) people. As a result, demand for peptide and anticoagulant drugs market has increased dramatically.

Peptide and Anticoagulant Drugs Market Size                              

Global peptide and anticoagulant drugs market size was valued at USD 1.83 billion in 2024 and is projected to reach USD 2.93 billion by 2032, with a CAGR of 6.10% during the forecast period of 2025 to 2032.

Report Scope and Market Segmentation       

Attributes

Peptide and Anticoagulant Drugs Key Market Insights

Segmentation

  • By Low Molecular Weight Heparin Type: Heparin Sodium, Enoxaparin Sodium, Dalteparin Sodium, and Fondaparinux
  • By Type: Hormonal, Antibiotic, ACE Inhibitor, Antifungal, Others
  • By Indication: Diabetes, Infectious Diseases, Cancer, Osteoporosis, Cardiology, Gynecology, Others
  • By Route of Administration: Oral, Injectable
  • By End User: Hospitals, Specialty Clinics, Homecare, Others
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Key Market Players

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Fresenius Kabi AG (Germany), Eisai Co., Ltd. (Japan),  Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED (Japan), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy's Laboratories Ltd. (India), Aspen Holdings (South Africa)

Market Opportunities

  • Increase in the number of research and development activities
  • Technological advancement

Peptide and Anticoagulant Drugs Market Definition

Blood thinners are anticoagulants, which are chemical agents that inhibit blood coagulation and blood clotting time. Anticoagulants are a pharmacological class of drugs used to treat thrombotic diseases. Oral anticoagulants come in pill, tablet, and injectable dose forms. Herapins, low molecular weight heparins (LMWHs), warfarin, direct thrombin inhibitors and factor Xa inhibitors are the most common anticoagulants (DTIs). Heparin is an injectable anticoagulant commonly used in hospitals to prevent blood clotting. Subcutaneous injections of LMWHs are given twice a day to treat DVT. Peptides, also known as amide bonds, are long-chain amino acids bound together by peptide bonds. Peptides are a special class of medicinal substances that are molecularly made up of tiny molecules and proteins. The therapeutic characteristics of peptides are deployed to treat a variety of disorders.

Peptide and Anticoagulant Drugs Market Dynamics

Drivers

  • Increasing cases of coronavirus infection globally

The rising coronavirus infection cases globally are anticipated to drive the peptide and anticoagulant drugs market's growth. According to new research, hypercoagulability in those infected by the coronavirus disease (COVID-19) pandemic could be one of the major causes of death globally. As a result, the rising number of instances is driving up demand for anticoagulant medications to treat thrombosis in critically unwell or hospitalized patients.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of peptide and anticoagulant drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Increasing prevalence of cardiovascular diseases

The increased prevalence of cardiovascular diseases will fuel industry growth. The rise in cardiovascular disorders is propelling the industry forward. Cardiovascular diseases are a major driver of market expansion. Cardiovascular disorders are the main cause of death worldwide, accounting for about 18.6 million deaths in 2019, as per the Heart Disease and Stroke Statistics Update Fact Sheet published in 2021. Each year, cardiovascular disorders cause more deaths than cancer and chronic lower respiratory disease (CLRD) combined. Additionally, increasing prevalence of chronic diseases in both the elderly and middle-aged populations is estimated to propel the market's growth rate.

Furthermore, surging geriatric population and rise in the number of infected patients globally will result in the expansion of peptide and anticoagulant drugs market. Along with this, the sedentary lifestyle of people such as rising addiction of smoking and extended sitting and favourable reimbursement policies will enhance the growth rate of the market.

Opportunities

  • Technological advancement

The industry is projected to benefit from technological advancements in the development of anticoagulant products. Advanced technologies such as microfluidics, fluorescent microscopy, electrochemical sensing, photoacoustic detection, and micro/nano electromechanical systems (MEMS/NEMS) have been used to develop highly accurate, robust, and cost-effective anticoagulant products, according to a study published in the Frontier in Biotehnology and Bioengineering in December 2019.

Moreover, the market's growth is fueled by an increase in the number of research and development activities and emerging new markets. These factors will provide beneficial opportunities for the peptide and anticoagulant drugs market growth.

Restraints/Challenges

  • Side effects linked with anticoagulants

Anticoagulant side effects may stymie market growth over the projection period. Heparin-induced thrombocytopenia causes the immune system to produce antibodies against the body's own platelets, which increases the risk of bleeding. For illustration, the FDA gets roughly 450,000 adverse medication events per year, with 3.8 percent of those involving heparin, reducing market income. Warfarin can also cause chrondrodysplasia punctata, asplenia, and foetal malformations, among other things. The industry's value will be harmed by such side consequences. Despite the fact that important market leaders are attempting to develop novel products, side effects may reduce their acceptance rate.

On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the market of peptide and anticoagulant drugs. Additionally, lack of awareness among people and strict government regulations will restrain and further impede the growth rate of the market during the forecast period of 2025-2032.

This peptide and anticoagulant drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the peptide and anticoagulant drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Peptide and anticoagulant drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Peptide and Anticoagulant Drugs Market Scope

The peptide and anticoagulant drugs market is segmented on the basis of type, indication, low molecular weight heparin type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Low Molecular Weight Heparin Type

  • Heparin Sodium
  • Enoxaparin Sodium
  • Dalteparin Sodium
  • Fondaparinux

Type

  • Hormonal
  • Antibiotic
  • ACE Inhibitor
  • Antifungal
  • Others

Indication

  • Diabetes
  • Infectious Diseases
  • Cancer
  • Osteoporosis
  • Cardiology
  • Gynecology
  • Others

Route of Administration

  • Oral
  • Injectable
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Peptide and Anticoagulant Drugs Market Regional Analysis

The peptide and anticoagulant drugs market is analysed and market size insights and trends are provided by country, type, indication, low molecular weight heparin type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the peptide and anticoagulant drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the peptide and anticoagulant drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing demand of diseases specific treatment and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the growing presence of major key players and rise in adoption of newer technologies will further propel themarket's growth rate in this region.

Asia-Pacific is expected to be the fastest growing region during the forecast period of 2025-2032 due to surging number of geriatric population in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel themarket's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Peptide and Anticoagulant Drugs Market Share

The peptide and anticoagulant drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to peptide and anticoagulant drugs market.

Peptide and Anticoagulant Drugs Market Leaders Operating in the Market Are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Ireland)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (U.S.)
  • Allergan (Ireland)
  • AstraZeneca (U.K.)
  • Johnson & Johnson Private Limited (U.S.)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Fresenius Kabi AG (Germany)
  • Eisai Co., Ltd. (Japan)
  • Bristol-Myers Squibb Company (U.S.)
  • Bayer AG (Germany)
  • DAIICHI SANKYO COMPANY, LIMITED (Japan)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Dr. Reddy's Laboratories Ltd. (India)
  • Aspen Holdings (South Africa)

Latest Developments in Peptide and Anticoagulant Drugs Market

  • In December 2020, Natco Pharma had announced the launch of an anticoagulant medication named Rivaroxaban (RPIGAT). Rivaroxaban is an anticoagulant drug that treats and prevents blood clots. In India, Bayer markets the drug as Xarelto.

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

Рынок сегментирован на основе Global Peptide and Anticoagulant Drugs Market Segmentation, By Low Molecular Weight Heparin Type (Heparin Sodium, Enoxaparin Sodium, Dalteparin Sodium, and Fondaparinux), Type (Hormonal, Antibiotic, ACE Inhibitor, Antifungal, Others), Indication (Diabetes, Infectious Diseases, Cancer, Osteoporosis, Cardiology, Gynecology, Others), Route of Administration (Oral, Injectable), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032 .
Размер Global Peptide and Anticoagulant Drugs Market в 2024 году оценивался в 1.83 USD Billion долларов США.
Ожидается, что Global Peptide and Anticoagulant Drugs Market будет расти со среднегодовым темпом роста (CAGR) 6.1% в течение прогнозируемого периода 2025–2032.
Отчет по рынку охватывает данные из U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Testimonial